Atom Investors’s Aclaris Therapeutics ACRS Stock Holding History

Atom Investors’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-22,343	Closed	-$153K	–	441
2023 Q3	$153K	Buy	+22,343	New	+$191K	0.03%	392
2021 Q4	–	Sell	-25,197	Closed	-$454K	–	264
2021 Q3	$454K	Sell	25,197 -157,393	-86%	-$2.52M	0.04%	208
2021 Q2	$3.21M	Buy	+182,590	New	+$4.15M	0.4%	40

Other funds holding ACRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Atom Investors's ACRS Position: Q4 2023 in Review

Atom Investors sold out of Aclaris Therapeutics (ACRS) in Q4 2023, closing a stake of 22,343 shares — an estimated $153K sold.

Atom Investors first reported a position in ACRS in Q2 2021 and held it in 3 quarters. The position peaked at $3.21M in Q2 2021. 107 funds tracked by Wall St. Rank hold ACRS as of Q4 2023.

Atom Investors reported no remaining Aclaris Therapeutics position as of Q4 2023 after selling out during the quarter.
Atom Investors sold 22,343 Aclaris Therapeutics shares in Q4 2023, an estimated $153K.
Atom Investors first reported a position in Aclaris Therapeutics in Q2 2021 and held it in 3 quarters.
Atom Investors's Aclaris Therapeutics position peaked at $3.21M in Q2 2021.
107 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2023.

Based on Atom Investors's 13F filing for Q4 2023, filed 14 Feb 2024.